GLPG1837 clinical trials
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2014
How each study uses GLPG1837 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
4 studies that test it; most in 2016 (2)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Studies
Open first, then newest update. How each study uses GLPG1837 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Study of GLPG1837 in Subjects With Cystic Fibrosis (G551D Mutation)CompletedPhase 2Galapagos NVNCT02707562Written as GLPG1837 dose 1
- Study of GLPG1837 in Subjects With Cystic Fibrosis (S1251N Mutation)CompletedPhase 2Galapagos NVNCT02690519Written as GLPG1837 dose 1
- A Phase I, Open Interaction Study Between GLPG1837 and Midazolam in Healthy Male SubjectsCompletedPhase 1Galapagos NVNCT02562950Written as GLPG1837 500 mg
- First-in-Human Single and Multiple Dose of GLPG1837CompletedPhase 1Galapagos NVNCT02325037Written as GLPG1837 single ascending doses